• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在下午3点的情境下,对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白/血管紧张素转换酶2(ACE2)蛋白质-蛋白质相互作用进行建模,以预测新的刺突蛋白变体与ACE2以及与ACE2结构相关的新型人类蛋白质靶点的结合亲和力,用于新冠疫情应对。

Modeling SARS-CoV-2 spike/ACE2 protein-protein interactions for predicting the binding affinity of new spike variants for ACE2, and novel ACE2 structurally related human protein targets, for COVID-19 handling in the 3PM context.

作者信息

Tragni Vincenzo, Preziusi Francesca, Laera Luna, Onofrio Angelo, Mercurio Ivan, Todisco Simona, Volpicella Mariateresa, De Grassi Anna, Pierri Ciro Leonardo

机构信息

Department of Biosciences, Biotechnologies, Biopharmaceutics, University of Bari, Via E. Orabona, 4, 70125 Bari, Italy.

Department of Sciences, University of Basilicata, Viale dell'Ateneo Lucano, 10-85100 Potenza, Italy.

出版信息

EPMA J. 2022 Jan 6;13(1):149-175. doi: 10.1007/s13167-021-00267-w. eCollection 2022 Mar.

DOI:10.1007/s13167-021-00267-w
PMID:35013687
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8732965/
Abstract

AIMS

The rapid spread of new SARS-CoV-2 variants has highlighted the crucial role played in the infection by mutations occurring at the SARS-CoV-2 spike receptor binding domain (RBD) in the interactions with the human ACE2 receptor. In this context, it urgently needs to develop new rapid tools for quickly predicting the affinity of ACE2 for the SARS-CoV-2 spike RBD protein variants to be used with the ongoing SARS-CoV-2 genomic sequencing activities in the clinics, aiming to gain clues about the transmissibility and virulence of new variants, to prevent new outbreaks and to quickly estimate the severity of the disease in the context of the 3PM.

METHODS

In our study, we used a computational pipeline for calculating the interaction energies at the SARS-CoV-2 spike RBD/ACE2 protein-protein interface for a selected group of characterized infectious variants of concern/interest (VoC/VoI). By using our pipeline, we built 3D comparative models of the SARS-CoV-2 spike RBD/ACE2 protein complexes for the VoC B.1.1.7-United Kingdom (carrying the mutations of concern/interest N501Y, S494P, E484K at the RBD), P.1-Japan/Brazil (RBD mutations: K417T, E484K, N501Y), B.1.351-South Africa (RBD mutations: K417N, E484K, N501Y), B.1.427/B.1.429-California (RBD mutations: L452R), the B.1.141 (RBD mutations: N439K), and the recent B.1.617.1-India (RBD mutations: L452R; E484Q) and the B.1.620 (RBD mutations: S477N; E484K). Then, we used the obtained 3D comparative models of the SARS-CoV-2 spike RBD/ACE2 protein complexes for predicting the interaction energies at the protein-protein interface.

RESULTS

Along SARS-CoV-2 mutation database screening and mutation localization analysis, it was ascertained that the most dangerous mutations at VoC/VoI spike proteins are located mainly at three regions of the SARS-CoV-2 spike "boat-shaped" receptor binding motif, on the RBD domain. Notably, the P.1 Japan/Brazil variant present three mutations, K417T, E484K, N501Y, located along the entire receptor binding motif, which apparently determines the highest interaction energy at the SARS-CoV-2 spike RBD/ACE2 protein-protein interface, among those calculated. Conversely, it was also observed that the replacement of a single acidic/hydrophilic residue with a basic residue (E484K or N439K) at the "stern" or "bow" regions, of the boat-shaped receptor binding motif on the RBD, appears to determine an interaction energy with ACE2 receptor higher than that observed with single mutations occurring at the "hull" region or with other multiple mutants. In addition, our pipeline allowed searching for ACE2 structurally related proteins, i.e., THOP1 and NLN, which deserve to be investigated for their possible involvement in interactions with the SARS-CoV-2 spike protein, in those tissues showing a low expression of ACE2, or as a novel receptor for future spike variants. A freely available web-tool for the in silico calculation of the interaction energy at the SARS-CoV-2 spike RBD/ACE2 protein-protein interface, starting from the sequences of the investigated spike and/or ACE2 variants, was made available for the scientific community at: https://www.mitoairm.it/covid19affinities.

CONCLUSION

In the context of the PPPM/3PM, the employment of the described pipeline through the provided webservice, together with the ongoing SARS-CoV-2 genomic sequencing, would help to predict the transmissibility of new variants sequenced from future patients, depending on SARS-CoV-2 genomic sequencing activities and on the specific amino acid replacement and/or on its location on the SARS-CoV-2 spike RBD, to put in play all the possible counteractions for preventing the most deleterious scenarios of new outbreaks, taking into consideration that a greater transmissibility has not to be necessarily related to a more severe manifestation of the disease.

SUPPLEMENTARY INFORMATION

The online version contains supplementary material available at 10.1007/s13167-021-00267-w.

摘要

目的

新型严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变体的迅速传播凸显了SARS-CoV-2刺突受体结合域(RBD)发生的突变在与人类血管紧张素转换酶2(ACE2)受体相互作用中的感染过程中所起的关键作用。在此背景下,迫切需要开发新的快速工具,以便快速预测ACE2对SARS-CoV-2刺突RBD蛋白变体的亲和力,用于临床正在进行的SARS-CoV-2基因组测序活动,旨在获取有关新变体的传播性和毒力的线索,预防新的疫情爆发,并在疫情监测计划(3PM)的背景下快速评估疾病的严重程度。

方法

在我们的研究中,我们使用了一个计算流程来计算一组选定的具有特征的关注/感兴趣的传染性变体(VoC/VoI)在SARS-CoV-2刺突RBD/ACE2蛋白质-蛋白质界面的相互作用能。通过使用我们的流程,我们构建了SARS-CoV-2刺突RBD/ACE2蛋白质复合物的三维比较模型,用于关注变体B.1.1.7-英国(RBD携带关注/感兴趣的突变N501Y、S494P、E484K)、P.1-日本/巴西(RBD突变:K417T、E484K、N501Y)、B.1.351-南非(RBD突变:K417N、E484K、N501Y)、B.1.427/B.1.429-加利福尼亚(RBD突变:L452R)、B.1.141(RBD突变:N439K)以及最近的B.1.617.1-印度(RBD突变:L452R;E484Q)和B.1.620(RBD突变:S477N;E484K)。然后,我们使用获得的SARS-CoV-2刺突RBD/ACE2蛋白质复合物的三维比较模型来预测蛋白质-蛋白质界面的相互作用能。

结果

通过对SARS-CoV-2突变数据库的筛选和突变定位分析,确定了VoC/VoI刺突蛋白中最危险的突变主要位于SARS-CoV-2刺突“船形”受体结合基序的三个区域,即RBD结构域上。值得注意的是,P.1日本/巴西变体在整个受体结合基序上存在三个突变,K417T、E484K、N501Y,在所计算的变体中,这显然决定了SARS-CoV-2刺突RBD/ACE2蛋白质-蛋白质界面的最高相互作用能。相反,还观察到在RBD上船形受体结合基序的“船尾”或“船头”区域,用碱性残基(E484K或N439K)取代单个酸性/亲水性残基,似乎决定了与ACE2受体的相互作用能高于在“船体”区域发生的单突变或其他多个突变体所观察到的相互作用能。此外,我们的流程允许搜索与ACE2结构相关的蛋白质,即THOP1和NLN,在那些ACE2表达较低的组织中,或者作为未来刺突变体的新型受体,它们可能参与与SARS-CoV-2刺突蛋白的相互作用,值得研究。一个免费的网络工具已可供科学界使用,可根据所研究的刺突和/或ACE2变体的序列,在计算机上计算SARS-CoV-2刺突RBD/ACE2蛋白质-蛋白质界面的相互作用能,网址为:https://www.mitoairm.it/covid19affinities。

结论

在疫情监测计划(PPPM/3PM)的背景下,通过提供的网络服务使用所描述的流程,结合正在进行的SARS-CoV-2基因组测序,将有助于根据SARS-CoV-2基因组测序活动、特定的氨基酸替换和/或其在SARS-CoV-2刺突RBD上的位置,预测未来患者测序的新变体的传播性,采取所有可能的应对措施以防止新疫情爆发的最有害情况,同时考虑到更高的传播性不一定与更严重的疾病表现相关。

补充信息

在线版本包含可在10.1007/s13167-021-00267-w获取的补充材料。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd8a/8897545/4c4b12eab5f0/13167_2021_267_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd8a/8897545/a06a75473354/13167_2021_267_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd8a/8897545/f373e144f8f8/13167_2021_267_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd8a/8897545/2a51cbc8910a/13167_2021_267_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd8a/8897545/9475e28903a3/13167_2021_267_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd8a/8897545/86e0b48ab74a/13167_2021_267_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd8a/8897545/bf4aad4da0bf/13167_2021_267_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd8a/8897545/2e1f65df8881/13167_2021_267_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd8a/8897545/4c4b12eab5f0/13167_2021_267_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd8a/8897545/a06a75473354/13167_2021_267_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd8a/8897545/f373e144f8f8/13167_2021_267_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd8a/8897545/2a51cbc8910a/13167_2021_267_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd8a/8897545/9475e28903a3/13167_2021_267_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd8a/8897545/86e0b48ab74a/13167_2021_267_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd8a/8897545/bf4aad4da0bf/13167_2021_267_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd8a/8897545/2e1f65df8881/13167_2021_267_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd8a/8897545/4c4b12eab5f0/13167_2021_267_Fig8_HTML.jpg

相似文献

1
Modeling SARS-CoV-2 spike/ACE2 protein-protein interactions for predicting the binding affinity of new spike variants for ACE2, and novel ACE2 structurally related human protein targets, for COVID-19 handling in the 3PM context.在下午3点的情境下,对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白/血管紧张素转换酶2(ACE2)蛋白质-蛋白质相互作用进行建模,以预测新的刺突蛋白变体与ACE2以及与ACE2结构相关的新型人类蛋白质靶点的结合亲和力,用于新冠疫情应对。
EPMA J. 2022 Jan 6;13(1):149-175. doi: 10.1007/s13167-021-00267-w. eCollection 2022 Mar.
2
Emerging Variants of SARS-CoV-2 and Novel Therapeutics Against Coronavirus (COVID-19)严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的新变种及针对冠状病毒(COVID-19)的新型疗法
3
Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics.常见突变对 SARS-CoV-2 刺突 RBD 及其配体人 ACE2 受体结合亲和力和动力学的影响。
Elife. 2021 Aug 26;10:e70658. doi: 10.7554/eLife.70658.
4
Vaccine-escape and fast-growing mutations in the United Kingdom, the United States, Singapore, Spain, India, and other COVID-19-devastated countries.疫苗逃逸和快速突变在英国、美国、新加坡、西班牙、印度和其他受 COVID-19 肆虐的国家。
Genomics. 2021 Jul;113(4):2158-2170. doi: 10.1016/j.ygeno.2021.05.006. Epub 2021 May 15.
5
In silico investigations of heparin binding to SARS-CoV-2 variants with a focus at the RBD/ACE2 interface.针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变体,重点关注受体结合域(RBD)/血管紧张素转换酶2(ACE2)界面的肝素结合的计算机模拟研究。
Process Biochem. 2022 Apr;115:70-79. doi: 10.1016/j.procbio.2022.02.012. Epub 2022 Feb 17.
6
In vitro data suggest that Indian delta variant B.1.617 of SARS-CoV-2 escapes neutralization by both receptor affinity and immune evasion.体外数据表明,SARS-CoV-2 的印度德尔塔变异株 B.1.617 能够通过受体亲和力和免疫逃避来逃避中和作用。
Allergy. 2022 Jan;77(1):111-117. doi: 10.1111/all.15065. Epub 2021 Sep 14.
7
Higher infectivity of the SARS-CoV-2 new variants is associated with K417N/T, E484K, and N501Y mutants: An insight from structural data.SARS-CoV-2 新变体的传染性更高与 K417N/T、E484K 和 N501Y 突变有关:来自结构数据的见解。
J Cell Physiol. 2021 Oct;236(10):7045-7057. doi: 10.1002/jcp.30367. Epub 2021 Mar 23.
8
Structural Modeling of the SARS-CoV-2 Spike/Human ACE2 Complex Interface can Identify High-Affinity Variants Associated with Increased Transmissibility.SARS-CoV-2 刺突蛋白/人 ACE2 复合物界面的结构建模可以识别与传播性增加相关的高亲和力变体。
J Mol Biol. 2021 Jul 23;433(15):167051. doi: 10.1016/j.jmb.2021.167051. Epub 2021 May 14.
9
In Silico Investigation of the New UK (B.1.1.7) and South African (501Y.V2) SARS-CoV-2 Variants with a Focus at the ACE2-Spike RBD Interface.利用计算机模拟方法研究新型英国(B.1.1.7)和南非(501Y.V2)SARS-CoV-2 变异株,重点关注 ACE2-刺突 RBD 界面。
Int J Mol Sci. 2021 Feb 8;22(4):1695. doi: 10.3390/ijms22041695.
10
GB-2 blocking the interaction between ACE2 and wild type and mutation of spike protein of SARS-CoV-2.GB-2阻断ACE2与新型冠状病毒野生型及刺突蛋白突变体之间的相互作用。
Biomed Pharmacother. 2021 Oct;142:112011. doi: 10.1016/j.biopha.2021.112011. Epub 2021 Aug 5.

引用本文的文献

1
Interaction of SARS-CoV-2 and SARS-CoV-2 vaccines with renin angiotensin aldosterone system, clinical outcomes, and angiotensin (1-7) as a physiological treatment recommendation: hypothesis and theory article.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)及其疫苗与肾素-血管紧张素-醛固酮系统的相互作用、临床结局以及血管紧张素(1-7)作为一种生理性治疗建议:假说与理论文章
Front Med (Lausanne). 2025 Jul 10;12:1612442. doi: 10.3389/fmed.2025.1612442. eCollection 2025.
2
A combinatorial and computational Tandem approach towards a universal therapeutics against ACE2-mediated coronavirus infections.一种针对ACE2介导的冠状病毒感染的通用疗法的组合式和计算串联方法。
iScience. 2025 May 16;28(6):112687. doi: 10.1016/j.isci.2025.112687. eCollection 2025 Jun 20.
3

本文引用的文献

1
A Bioinformatics Approach for the Prediction of Immunogenic Properties and Structure of the SARS-COV-2 B.1.617.1 Variant Spike Protein.一种用于预测SARS-CoV-2 B.1.617.1变异株刺突蛋白免疫原性特征和结构的生物信息学方法。
Biomed Res Int. 2021 Oct 5;2021:7251119. doi: 10.1155/2021/7251119. eCollection 2021.
2
Animal experiments show impact of vaccination on reduction of SARS-CoV-2 virus circulation: A model for vaccine development?动物实验显示疫苗接种对减少 SARS-CoV-2 病毒传播的影响:疫苗开发的模型?
Biologicals. 2021 Sep;73:1-7. doi: 10.1016/j.biologicals.2021.08.001. Epub 2021 Sep 3.
3
N501Y mutation of spike protein in SARS-CoV-2 strengthens its binding to receptor ACE2.
Impact of SARS-CoV-2 RBM Mutations N501Y and E484K on ACE2 Binding: A Combined Computational and Experimental Study.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)受体结合基序(RBM)突变N501Y和E484K对血管紧张素转换酶2(ACE2)结合的影响:一项计算与实验相结合的研究
Int J Mol Sci. 2025 Apr 25;26(9):4064. doi: 10.3390/ijms26094064.
4
Combined in silico/in vitro approaches for identifying modulators of the activity of the p.Tyr110Cys Carnitine O-Acetyltransferase (CRAT) variant associated to an early onset case of Leigh syndrome.结合计算机模拟/体外实验方法鉴定与 Leigh 综合征早发病例相关的 p.Tyr110Cys 肉碱 O-乙酰转移酶(CRAT)变体活性调节剂。
Acta Pharmacol Sin. 2025 Apr;46(4):1123-1136. doi: 10.1038/s41401-024-01435-0. Epub 2024 Dec 16.
5
Insights into Transient Dimerisation of Carnitine/Acylcarnitine Carrier (SLC25A20) from Sarkosyl/PAGE, Cross-Linking Reagents, and Comparative Modelling Analysis.从 Sarkosyl/PAGE、交联试剂和比较建模分析中洞察肉碱/酰基辅酶 A 载体(SLC25A20)的瞬时二聚化。
Biomolecules. 2024 Sep 14;14(9):1158. doi: 10.3390/biom14091158.
6
A Comparative Analysis of Innate Immune Responses and the Structural Characterization of Spike from SARS-CoV-2 Gamma Variants and Subvariants.新冠病毒伽马变异株及其亚变异株天然免疫反应的比较分析与刺突蛋白的结构表征
Microorganisms. 2024 Apr 2;12(4):720. doi: 10.3390/microorganisms12040720.
7
Assessing the Clinical Impact of the SARS-CoV-2 Gamma Variant on Intensive Care Unit Admissions: Insights from a Reference Hospital in Northeastern Brazil.评估 SARS-CoV-2 伽马变异株对重症监护病房收治的临床影响:来自巴西东北部参考医院的见解。
Viruses. 2024 Mar 20;16(3):467. doi: 10.3390/v16030467.
8
Fast-Track Discovery of SARS-CoV-2-Neutralizing Antibodies from Human B Cells by Direct Functional Screening.直接功能筛选快速发现针对 SARS-CoV-2 的中和抗体的人 B 细胞。
Viruses. 2024 Feb 22;16(3):339. doi: 10.3390/v16030339.
9
Landscape of molecular crosstalk between SARS-CoV-2 infection and cardiovascular diseases: emphasis on mitochondrial dysfunction and immune-inflammation.SARS-CoV-2 感染与心血管疾病的分子串扰图谱:重点关注线粒体功能障碍和免疫炎症。
J Transl Med. 2023 Dec 16;21(1):915. doi: 10.1186/s12967-023-04787-z.
10
Multi-omic analysis characterizes molecular susceptibility of receptors to SARS-CoV-2 spike protein.多组学分析表征了受体对SARS-CoV-2刺突蛋白的分子易感性。
Comput Struct Biotechnol J. 2023 Nov 10;21:5583-5600. doi: 10.1016/j.csbj.2023.11.012. eCollection 2023.
SARS-CoV-2 刺突蛋白的 N501Y 突变增强了其与受体 ACE2 的结合。
Elife. 2021 Aug 20;10:e69091. doi: 10.7554/eLife.69091.
4
SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution.SARS-CoV-2 变体预测和抗病毒药物设计可通过 RBD 体外进化实现。
Nat Microbiol. 2021 Sep;6(9):1188-1198. doi: 10.1038/s41564-021-00954-4. Epub 2021 Aug 16.
5
Complex analysis of the personalized pharmacotherapy in the management of COVID-19 patients and suggestions for applications of predictive, preventive, and personalized medicine attitude.新型冠状病毒肺炎患者个体化药物治疗的复杂性分析以及预测、预防和个体化医学态度的应用建议
EPMA J. 2021 Jul 16;12(3):307-324. doi: 10.1007/s13167-021-00247-0. eCollection 2021 Sep.
6
Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay.通过多重分析同时评估抑制 SARS-CoV-2 变体的抗体。
JCI Insight. 2021 Aug 23;6(16):e150012. doi: 10.1172/jci.insight.150012.
7
SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern.关注变异株 B.1.427/B.1.429 逃避 SARS-CoV-2 免疫。
Science. 2021 Aug 6;373(6555):648-654. doi: 10.1126/science.abi7994. Epub 2021 Jul 1.
8
SARS-CoV-2 virulence evolution: Avirulence theory, immunity and trade-offs.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的毒力进化:无毒力理论、免疫与权衡
J Evol Biol. 2021 Dec;34(12):1867-1877. doi: 10.1111/jeb.13896. Epub 2021 Jul 17.
9
Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.针对关注的 SARS-CoV-2 变体的中和抗体的表位分类和 RBD 结合特性。
Front Immunol. 2021 Jun 4;12:691715. doi: 10.3389/fimmu.2021.691715. eCollection 2021.
10
An ACE2 Triple Decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants.一种能中和 SARS-CoV-2 的 ACE2 三聚体诱饵具有增强对病毒变异株的亲和力。
Sci Rep. 2021 Jun 17;11(1):12740. doi: 10.1038/s41598-021-91809-9.